BackPT Bundamedik Tbk Overview

PT Bundamedik Tbk EBIT

PT Bundamedik Tbk's EBIT is $78B, below the sector sector average of $2.4T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$25.52B
↓ 23.09% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

$78.38B
↓ 21.9% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

PT Bundamedik Tbk (BMHS.JK) FAQ

The latest EBIT for BMHS.JK is $78B as of September 2026. That compares with $100B in the prior-year period — down 21.9% year over year. That is below the sector sector average of $2.4T. Investors often review this figure alongside PT Bundamedik Tbk's historical trend and sector peers before judging valuation or financial health.

Over the past year, BMHS.JK's EBIT moved from $100B to $78B — a 21.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in PT Bundamedik Tbk's operating scale or balance-sheet position.

Against its sector companies, BMHS.JK currently prints $78B for EBIT, while the sector average sits near $2.4T. That is roughly 96.7% below the sector mean. Large gaps often invite a closer look at PT Bundamedik Tbk's growth, margins, and balance sheet.

A EBIT figure of $78B for BMHS.JK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.4T. Explore the charts below for those layers of context.

After noting BMHS.JK's EBIT ($78B), review year-over-year change from $100B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers